This project aims to advance the development of a new, patented medicine, designed to treat lung cancer. It is a small-molecule therapy that works by targeting a key immune-related protein linked to cancer progression. Our research focuses on patients who naturally produce higher levels of a molecule known as MIF—a group that represents nearly half of all people with lung cancer. By identifying and treating those most likely to respond, we’re working toward a more precise and effective therapy that offers real benefit where it’s needed most.
